Qlaris Bio Announces First Patient Dosed in Phase II Nightingale Clinical Trial in Normal Tension Glaucoma Patients

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that the first patient has been dosed in the company’s Phase II Nightingale clinical trial evaluating QLS‑111, the company’s lead investigational therapy, in patients with normal tension glaucoma (NTG). The Nightingale study is Qlaris Bio’s third Phase II clinical trial of QLS‑111 and will seek to build upon the positive clinical dat